Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novo Nordisk, Sanofi, and Eli Lilly Lead in the $12 Billion U.S. Diabetes Market

Published: Monday, July 15, 2013
Last Updated: Monday, July 15, 2013
Bookmark and Share
As diabetes rates reach alarming rates in the United States the market for diagnostics and treatment of the illness grows.

According to the latest statistics recorded by the American Diabetes Association, over 25 million children and adults in the United States were suffering from diabetes in 2011. Moreover, it is estimated that there are 79 million people who are prediabetic. People with prediabetes have an increased risk of becoming diabetic and are susceptible to the complications associated with the disease. However, if patients take action to better manage their blood glucose, they can delay or prevent diabetes from developing. The illness is the seventh leading cause of death in the U.S. and contributes to other maladies such as heart disease, stroke, blindness, amputations, and kidney failure.

According to the latest intelligence from iData Research, the market for diabetes monitoring, diagnosis, treatment, and drug delivery is valued at nearly $12 billion. With its success in treating both type 1 and type 2 diabetes, insulin represents the largest portion of the market. “This market is expected to maintain strong growth, and will be spurred by factors such as the number of diabetics, obesities, and alternative modes of delivery, such as insulin pens, pumps, and patches,” explains Dr. Kamran Zamanian, CEO of iData Research. “Units of insulin pens, for example, are expected to grow at double-digit rates, as newly diagnosed diabetics who are prescribed insulin are better informed of the conveniences of an insulin pen.” The dominant pen manufacturers are investing heavily in marketing, and the promotional backing is proving to be a very strong market driver.

Due to its great presence in both the insulin and insulin pen market in the U.S., Novo Nordisk is the market leader, dominating close to a quarter of the total market with products such as the NovoLog® and Novolin®R insulin products, and FlexPen®, NovoPen®, and NovoLet® insulin pens. Sanofi and Eli Lilly occupy the second and third places in the total market, respectively, competing with Novo Nordisk in the insulin and insulin pen markets. Lifescan and Roche Diagnostics are also large players, working primarily in the diabetes diagnostics sector. Lifescan is very involved in the diabetes community and is working to improve patient education and patient quality of life through development of new drugs, supporting legislation and healthcare reform to benefit people with diabetes. Roche Diagnostics is focused on innovation and forward-thinking solutions for healthcare. Their comprehensive portfolio includes products for reference labs, hospital labs, blood banks and specialty testing.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!